Compare FDP & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | MESO |
|---|---|---|
| Founded | 1886 | 2004 |
| Country | Cayman Islands | Australia |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 1997 | N/A |
| Metric | FDP | MESO |
|---|---|---|
| Price | $38.26 | $18.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 251.7K | 206.1K |
| Earning Date | 10-29-2025 | 08-28-2025 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | ★ 413.60 | N/A |
| EPS | ★ 1.64 | N/A |
| Revenue | ★ $4,316,000,000.00 | $17,198,000.00 |
| Revenue This Year | $1.82 | $465.44 |
| Revenue Next Year | N/A | $75.37 |
| P/E Ratio | $23.28 | ★ N/A |
| Revenue Growth | 0.94 | ★ 191.39 |
| 52 Week Low | $26.50 | $9.61 |
| 52 Week High | $40.75 | $22.00 |
| Indicator | FDP | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 65.30 | 63.50 |
| Support Level | $36.05 | $16.43 |
| Resistance Level | $37.43 | $17.65 |
| Average True Range (ATR) | 0.79 | 0.63 |
| MACD | 0.13 | 0.31 |
| Stochastic Oscillator | 97.87 | 82.14 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.